Nymox Pharmaceutical (NYMXF) 6-K 15 Aug 22 2022 Q2 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	Nymox Pharmaceutical Corporation
Entity Central Index Key	0001018735
Document Type	6-K
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity File Number	001-12033
Entity Address Postal Zip Code	20549

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues
Sales of goods	$ 0	$ 0	$ 0	$ 5
Total revenues	0	0	0	5
Operating expenses
Research and development	810	2,068	5,144	3,493
General and administrative	963	1,912	1,703	2,915
Marketing	0	0	0	0
Cost of sales	0	0	0	4
Total expenses	1,773	3,980	6,847	6,408
Loss from operations	(1,773)	(3,980)	(6,847)	(6,408)
Other Income/Expense
Other income	3,117		3,117
Operating lease and financial obligations	(3)	(4)	(10)	(10)
Interest income (cost)	(1)	(6)	(6)	(11)
Loss before income tax	1,340	(3,990)	(3,746)	(6,429)
Income tax provision (recovery)	0	0	0	0
Net loss	$ 1,340	$ (3,990)	$ (3,746)	$ (6,429)
Net income(loss) per share Basic	$ 0.01	$ (0.05)	$ (0.04)	$ (0.08)
Weighted average number of common shares outstanding	90,420	81,490	88,235	79,739
Net income(loss) per share Diluted	$ 0.01	$ (0.05)	$ (0.04)	$ (0.08)
Weighted average number of diluted shares outstanding	105,439	81,490	88,235	79,739

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash at bank	$ 4,070	$ 830
Other receivables	9	13
Inventory	34	34
Security deposit	28	28
Prepaid expenses and other current assets	44	132
Total current assets	4,185	1,037
Non-current assets
Property and equipment	16	22
Operating lease right-of-use asset, net	273	384
Total assets	4,474	1,443
Current liabilities
Accounts payable and accrued liabilities	1,958	1,558
Operating lease liability due within one year	232	228
Total current liability	2,190	1,786
Long term operating lease liability	52	163
Total liabilities	2,242	1,949
Equity
Share capital - unlimited authorized shares at no par value 91,265 and 85,546 shares outstanding at June 30, 2022 and December 31, 2021, respectively	172,260	165,061
Share capital subscription receivable	(589)	(589)
Additional paid-in capital	26,869	27,584
Accumulated deficit	(196,308)	(192,562)
Total stockholders' equity	2,232	(506)
Total liabilities and stockholders' equity	$ 4,474	$ 1,443

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Parenthetical) - shares shares in Thousands	Jun. 30, 2022	Dec. 31, 2021
Consolidated Statements of Financial Position (Unaudited)
Share capital, shares outstanding	91,265	85,546

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,746)	$ (6,429)
Adjustments for:
Stock-based compensation	476	1,708
Depreciation	6	6
Amortization and others	121	121
Changes in non-cash operating balances:
Accounts receivable and other receivables	4	5
Prepaid expenses and other current asset	89	143
Accounts payable and accrued liabilities	400	(125)
Net cash used in operating activities	(2,650)	(4,571)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	0	(2)
Net cash flows used in investing activities	0	(2)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of share capital	6,007	7,283
Repayment of operating lease and financing obligation	(117)	(120)
Net cash flows used in financing activities	5,890	7,163
Net increase in cash and cash equivalents	3,240	2,590
CASH AT BANK
Beginning of the period	830	3,611
End of the period	4,070	6,201
NON-CASH INVESTING AND FINANCING ACTIVITIES
Operating lease right-of-use asset and related liability	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in (Deficit) Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Number of Common Shares	Share Capital Subscription	Accumulated Deficit	Additional Paid-In Capital
Balance, shares at Dec. 31, 2020		77,961
Balance, amount at Dec. 31, 2020	$ 2,145	$ 151,722	$ (589)	$ (180,025)	$ 31,037
Statement [Line Items]
Share issuance for cash and share subscription, shares		3,670
Share issuance for cash and share subscription, amount	6,953	$ 7,670			(717)
Warrants issued	330				330
Stock-based compensation and service fee, shares		2,100
Stock-based compensation and service fee, amount	1,708	$ 3,072		0	(1,364)
Net loss	(6,429)	0	0	(6,429)	0
Balance, amount at Jun. 30, 2021	4,707	$ 162,464	(589)	(186,454)	29,286
Balance, shares at Jun. 30, 2021		83,731
Balance, shares at Dec. 31, 2021		85,546
Balance, amount at Dec. 31, 2021	(506)	$ 165,061	(589)	(192,562)	27,584
Statement [Line Items]
Share issuance for cash and share subscription, shares		3,984
Share issuance for cash and share subscription, amount	4,266	$ 4,834			(568)
Warrants issued	1,741				1,741
Stock-based compensation and service fee, amount	477	2,365		0	(1,888)
Net loss	(3,746)	$ 0	0	(3,746)	0
Stock-based compensation and service fee, shares		1,735
Balance, amount at Jun. 30, 2022	$ 2,232	$ 172,260	$ (589)	$ (196,308)	$ 26,869
Balance, shares at Jun. 30, 2022		91,265

Basis of preparation

Basis of preparation	6 Months Ended
	Jun. 30, 2022
Basis of preparation	1. Basis of preparation: (a) Statement of compliance: The consolidated condensed unaudited interim consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34, Interim Financial Reporting The consolidated condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on August 12, 2022. (b) Basis of measurement: The condensed unaudited interim consolidated financial statements have been prepared on a going concern and on the historical cost basis. The functional currency of the Corporation is the US dollar. (c) Use of estimates and judgments: The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below: Significant estimates include, but are not limited to, the estimation of useful lives of equipment for purposes of depreciation, useful life of lease for purpose of amortization and the valuation of common shares and stock option issued for services.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Managements Response	6 Months Ended
	Jun. 30, 2022
Liquidity, Going Concern and Management's Response	2. Liquidity, Going Concern and Management’s Response: Management believes that current cash balances as of June 30, 2022 and planed fund raising is sufficient to finance the Company’s operations for at least the next 12 months. However, if necessary, the Company intends to seek additional equity or other financing, should the Company’s liquidity need change. Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. These financial statements do not reflect adjustments that would be necessary. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such an adjustment could be material.

Share capital

Share capital	6 Months Ended
	Jun. 30, 2022
Share capital	3. Share Capital: The holders of common shares are entitled to receive dividends as declared, which is at the discretion of the Corporation, and are entitled to one vote per share at the annual general meeting of the Corporation. The Corporation has never paid any dividends. (a) Private placements: On March 18, 2022, the company entered into a definitive agreement with institutional investors in a private placement of 3,878,789 shares of common stock and warrants to purchase 3,878,789 shares of common stock at a combined purchase price of $1.65 per share for gross proceeds of approximately $6,400,000 before deducting fees and other estimated offering expenses. The investor warrants have an exercise price of $2.00 per share, is immediately exercisable and will expire five years from the Effective Date. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement. On March 22, the company closed its financing. (b) Stock options: The Corporation has established a stock option plan (the “Plan”) for its key employees, its officers and directors, and certain consultants. The Plan is administered by the Board of Directors of the Corporation. The Board may from time to time designate individuals to whom options to purchase common shares of the Corporation may be granted, the number of shares to be optioned to each, and the option price per share. The option price per share cannot involve a discount to the market price at the time the option is granted. The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire ten years after the grant date and vest either immediately or over periods up to six years, and are equity-settled. As of June 30, 2022, 8,572,000 options could still be granted by the Corporation. The following table provides the activity of stock option awards during the six-month period ended June 30, 2022 and for options outstanding and exercisable at the end of the six-month period ended June 30, 2022, the weighted average exercise price and the weighted average years to expiration. Outstanding Weighted Weighted average average remaining exercise contractual Number Price life (in years) Outstanding, December 31, 2021 6,428,000 $ 1.81 3.86 Expired / Cancelled - - - Granted - - - Outstanding, June 30, 2022 6,428,000 $ 1.81 3.36 Options exercisable 6,373,833 $ 1.80 3.32 (c) Stock-based compensation: Stock -based compensation includes stock and stock option granted to employees and contractors Three months Six months ended June 30, ended June 30, Employee expenses 2022 2021 2022 2021 Stock options and compensation granted in: 2015 24,482 184,827 86,749 414,015 2020 32,369 52,858 64,738 105,716 2021 - 1,187,959 - 1,187,959 2022 324,777 - 324,777 - Total stock-based compensation expense recognized $ 381,628 $ 1,425,644 $ 476,264 $ 1,707,690 The stock-based compensation expense is disaggregated in the statements of operations and comprehensive loss as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Stock-based compensation pertaining to general and administrative $ 337,018 $ 1,280,372 $ 368,151 $ 1,394,966 Stock-based compensation pertaining to research and development 44,610 145,272 108,113 312,724 Total $ 381,628 $ 1,425,644 $ 476,264 $ 1,707,690 (d) Warrants : In the first quarter of 2019, the Corporation issued 2,500,000 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $8.00 with a seven years term. The warrant was valued at $200,000 and recorded as part of additional paid in capital. In the second quarter of 2021, the Corporation issued 2,018,348 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.50 with a five year term. The warrant was recorded as part of additional paid in capital at a total of $330,277. In the first quarter of 2022, the Corporation issued 3,878,789 investor warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.00 with a five year term. In addition, the Company issued Placement Agent (or its assigns) warrants to purchase up to 193,939 shares of common stock at an exercise price of $2.06 per share, The Placement Agent Warrants are immediately exercisable and will expire on the five-year anniversary of the Effective Date. The warrants were recorded as part of additional paid in capital at a total of $1,877,608.

Earnings per share

Earnings per share	6 Months Ended
	Jun. 30, 2022
Earnings per share
Earnings per share:	4. Earnings per Share: Weighted average number of common shares outstanding: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Issued common shares at beginning of period 90.279,794 78,711,151 85,545,875 77,961,151 Effect of shares issued 140,139 2,778,823 2,689,564 1,778,303 Weighted average number of common shares outstanding - basic 90,419,933 81,489,974 88,235,439 79,739,454 Weighted average number of shares outstanding - diluted 105,439,009 81,489,974 88,235,439 79,739,454 There is no difference in diluted as compared to basic earnings per share for the period when the company has a net loss as the impact would be antidilutive.

Operating leases and other comm

Operating leases and other commitments	6 Months Ended
	Jun. 30, 2022
Operating leases and other commitments	5. Operating leases and other commitments Effective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. We used an incremental borrowing rate as a discount rate for our operating leases. The discount rate ranges from 4.75% to 5.00%. The average remaining years for our lease are 1.21 years as of June 30, 2022. The following table provides the changes in the Corporation’s operating lease right-of-use assets for the six months ended June 30, 2022 and year end of December 31, 2021 respectively: (amounts in dollars) Total Balances as of January 1, 2022 $ 383,969 Renewed office lease - Accumulated amortization (110,997 ) Balances as of June 30, 2022 $ 272,972 (amounts in dollars) Total Balances as of January 1, 2021 $ 422,297 Renewed office lease 184,160 Accumulated amortization (222,488 ) Balances as of December 31, 2021 $ 383,969 The following table provides the changes in the Corporation’s operating lease liability for the six months ended June 30, 2022 and year end of 2021 respectively: (amounts in dollars) Total Balances as of January 1, 2022 $ 391,459 Renewed office lease - Repayments of lease liability (117,039 ) Other 9,657 Balances as of June 30, 2022 $ 284,077 Lease liability due within one year $ 232,222 Lease liability long term $ 51,855 (amounts in dollars) Total Balances as of January 1, 2021 $ 425,620 Renewed office lease 184,160 Repayments of lease liability (237,574 ) Other 19,253 Balances as of December 31, 2021 $ 391,459 Lease liability due within one year $ 228,651 Lease liability long term $ 162,808 The total future commitment payment amount for above lease is $292,240 comparing an outstanding lease liability of $284,077 as of June 30, 2022. The difference is due to interest expense. In addition to the lease commitment, the corporation has a future insurance premium payment and copier rent of $2,771 as of June, 30,2022.

New Drug Application (NDA) fee

New Drug Application (NDA) fee refund	6 Months Ended
	Jun. 30, 2022
New Drug Application (NDA) fee refund	6. New Drug Application (NDA) fee refund : In March, 2022, the Company submitted it’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH). The company paid a total of $3,117,218 for the application fee and recorded as R&D expense. Following the FDA guidance of industry user fee waivers, reductions and refund for drug products, the Company expects it will receive a full refund for the application fee. In May, 2022, the company received a full refund of the NDA fee and recorded it as other income.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transaction	7. Related Party Transactions: The transactions we have with related parties include compensation arrangements for current compensation, share based compensation, and compensation under options, and share purchase as investor. Executive officers and directors participate in the Corporation’s stock option plan. Certain Executive officers are covered under the Corporation’s health plan. Key management personnel compensation is comprised of: Three months Six months ended June 30, ended June 30, 2022 2021 2022 2021 Salaries and bonus 60,000 - 360,000 250,000 Short-term employee benefits 598 602 1,181 1,185 Stock-based compensation 349,259 184,827 411,526 414,015 $ 409,857 $ 185,429 $ 772,707 665,200 Total honorariums to the independent directors of the Corporation for participating in Board and Committee meetings were nil for the period ended June 30, 2022 and 2021, respectively. On June 28, 2022, the company accepted the resignation of the CFO. The former Chief Financial Officer received no compensation as an individual and received no deferred or incentive compensation. We do make payments based on contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $40,000 for the period ended June 30, 2022 and $240,000 for the period ended June 30, 2021, respectively. On May 11, 2022, the company issued 235,346 shares to James G. Robinson in consideration for his long and outstanding service to the company. The total value of the compensation shares is $324,777 . Our Corporate Legal Counsel receives no salary compensation as an individual and receives no deferred or incentive compensation. We do make payments based on contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $242,500 for the period ended June 30, 2022 and $173,464 for the period ended June 30, 2021, respectively. One of directors, James G. Robinson, purchased 1,151,515 shares of common stock at a purchase price of $1.65 per share for a total value of 1.9M in the company’s financing in March, 2022. Concurrently with the closing of the Offering, he received warrants to purchase up to an aggregate of 1,151,515 shares of common stock, at an initial exercise price equal to $2.00 per share and will expire on the five-year anniversary of the Effective Date.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2022
Subsequent events	8. Subsequent events: The Corporation has evaluated subsequent events through August 12, 2022, the date the financial statements were authorized for issuance by the Audit Committee of the Board of Directors. The Corporation has determined there are no subsequent events.

Basis of preparation (Policies)

Basis of preparation (Policies)	6 Months Ended
	Jun. 30, 2022
Statement of compliance	The consolidated condensed unaudited interim consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34, Interim Financial Reporting The consolidated condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on August 12, 2022.
Basis of measurement	The condensed unaudited interim consolidated financial statements have been prepared on a going concern and on the historical cost basis. The functional currency of the Corporation is the US dollar.
Use of estimates and judgments	The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below: Significant estimates include, but are not limited to, the estimation of useful lives of equipment for purposes of depreciation, useful life of lease for purpose of amortization and the valuation of common shares and stock option issued for services.

Share capital (Tables)

Share capital (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Stock option award	Outstanding Weighted Weighted average average remaining exercise contractual Number Price life (in years) Outstanding, December 31, 2021 6,428,000 $ 1.81 3.86 Expired / Cancelled - - - Granted - - - Outstanding, June 30, 2022 6,428,000 $ 1.81 3.36 Options exercisable 6,373,833 $ 1.80 3.32
Summary of stock option-based compensation	Three months Six months ended June 30, ended June 30, Employee expenses 2022 2021 2022 2021 Stock options and compensation granted in: 2015 24,482 184,827 86,749 414,015 2020 32,369 52,858 64,738 105,716 2021 - 1,187,959 - 1,187,959 2022 324,777 - 324,777 - Total stock-based compensation expense recognized $ 381,628 $ 1,425,644 $ 476,264 $ 1,707,690
Summary of stock option-based compensation expense	Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Stock-based compensation pertaining to general and administrative $ 337,018 $ 1,280,372 $ 368,151 $ 1,394,966 Stock-based compensation pertaining to research and development 44,610 145,272 108,113 312,724 Total $ 381,628 $ 1,425,644 $ 476,264 $ 1,707,690

Earning Per Share (Tables)

Earning Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Weighted average number of common shares outstanding	Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Issued common shares at beginning of period 90.279,794 78,711,151 85,545,875 77,961,151 Effect of shares issued 140,139 2,778,823 2,689,564 1,778,303 Weighted average number of common shares outstanding - basic 90,419,933 81,489,974 88,235,439 79,739,454 Weighted average number of shares outstanding - diluted 105,439,009 81,489,974 88,235,439 79,739,454

Operating leases and other co_2

Operating leases and other commitment (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Operating lease right-of-use assets	(amounts in dollars) Total Balances as of January 1, 2022 $ 383,969 Renewed office lease - Accumulated amortization (110,997 ) Balances as of June 30, 2022 $ 272,972 (amounts in dollars) Total Balances as of January 1, 2021 $ 422,297 Renewed office lease 184,160 Accumulated amortization (222,488 ) Balances as of December 31, 2021 $ 383,969
Summary of operating lease liability	(amounts in dollars) Total Balances as of January 1, 2022 $ 391,459 Renewed office lease - Repayments of lease liability (117,039 ) Other 9,657 Balances as of June 30, 2022 $ 284,077 Lease liability due within one year $ 232,222 Lease liability long term $ 51,855 (amounts in dollars) Total Balances as of January 1, 2021 $ 425,620 Renewed office lease 184,160 Repayments of lease liability (237,574 ) Other 19,253 Balances as of December 31, 2021 $ 391,459 Lease liability due within one year $ 228,651 Lease liability long term $ 162,808

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Schedule of key management personnel compensation	Three months Six months ended June 30, ended June 30, 2022 2021 2022 2021 Salaries and bonus 60,000 - 360,000 250,000 Short-term employee benefits 598 602 1,181 1,185 Stock-based compensation 349,259 184,827 411,526 414,015 $ 409,857 $ 185,429 $ 772,707 665,200

Share capital (Details)

Share capital (Details) - Equity Option [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Statement [Line Items]
Number of outstanding balance, Beginning | shares	6,428,000
Expired / Cancelled | shares	0
Granted | shares	0
Number of outstanding balance, Ending | shares	6,428,000
Options exercisable | shares	6,373,833
Weighted average exercise price, Beginning | $ / shares	$ 1.81
Weighted average exercise price, Expired / Cancelled | $ / shares	0
Weighted average exercise price, Granted | $ / shares	0
Weighted average exercise price, Ending | $ / shares	1.81
Weighted average exercise price, Options exercisable | $ / shares	$ 1.80
Weighted average remaining contractual life (in years), Beginning	3 years 10 months 9 days
Weighted average remaining contractual life (in years), Granted	0 years
Weighted average remaining contractual life (in years), Ending	3 years 4 months 9 days
Weighted average remaining contractual life options exercisable (in years)	3 years 3 months 25 days

Share capital (Details 1)

Share capital (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
2020 [Member]
Statement [Line Items]
Shares based compensation recognized expense	$ 32,369	$ 52,858	$ 64,738	$ 105,716
2021 [Member]
Statement [Line Items]
Shares based compensation recognized expense	0	1,187,959	0	1,187,959
2022 [Member]
Statement [Line Items]
Shares based compensation recognized expense	324,777	0	324,777	0
2015 [Member]
Statement [Line Items]
Shares based compensation recognized expense	24,482	184,827	86,749	414,015
Total [Member]
Statement [Line Items]
Shares based compensation recognized expense	$ 381,628	$ 1,425,644	$ 476,264	$ 1,707,690

Share capital (Details 2)

Share capital (Details 2) - Equity Option [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement [Line Items]
Stock-based compensation pertaining to general and administrative expenses	$ 337,018	$ 1,280,372	$ 368,151	$ 1,394,966
Stock-based compensation pertaining to research and development expenses	44,610	145,272	108,113	312,724
Total	$ 381,628	$ 1,425,644	$ 476,264	$ 1,707,690

Share capital (Details Narrativ

Share capital (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2019	Jun. 30, 2022	Jun. 30, 2021
Private Placements [Member]
Statement [Line Items]
Warrants issued	2,500,000	3,878,789	2,018,348
Combined purchase price		$ 1.65
Warrant value	$ 200,000		$ 330,277
Exercise price or warrants	$ 8	$ 2	$ 2.50
Gross proceeds of before deducting fees		$ 6,400,000
Common stock shares issued		193,939
Common stock exercise price		$ 2.06
Warrants of additional paid in capital		$ 1,877,608
Private Placements [Member] | Investor [Member]
Statement [Line Items]
Warrants issued		3,878,789
Stock Option [Member]
Statement [Line Items]
Options available for granting		8,572,000
Shares issuable upon exercise of warrants, maximum		15,000,000
Percentage of issued and outstanding shares issuable maximum to one individual		15%

Earnings per share (Details)

Earnings per share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Issued common shares at beginning of period	90,279,794	78,711,151	85,545,875	77,961,151
Effect of shares issued	140,139	2,778,823	2,689,564	1,778,303
Weighted average number of common shares outstanding - basic	90,419,933	81,489,974	88,235,439	79,739,454
Weighted average number of shares outstanding - diluted	105,439,009	81,489,974	88,235,439	79,739,454

Operating leases and other co_3

Operating leases and other commitment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Begininng balance	$ 383,969	$ 422,297
Renewed office lease	0	184,160
Accumulated amortization	(110,997)	(222,488)
Ending balance	$ 272,972	$ 383,969

Operating leases and other co_4

Operating leases and other commitment (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Beginning balance	$ 391,459	$ 425,620
Renewed office lease	0	184,160
Repayments of lease liability	(117,039)	(237,574)
Other	9,657	19,253
Ending balance	284,077	391,459
Lease liability due within one year	232,222	228,651
Lease liability long term	$ 51,855	$ 162,808

Operating leases and other co_5

Operating leases and other commitment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement [Line Items]
Operating lease liability	$ 284,077	$ 391,459	$ 425,620
Future payment amount and copier rent	2,771
Future payment amount	292,240
January 1, 2019 [Member]
Statement [Line Items]
Immaterial cumulative adjustment	$ 11,667
Description average remaining life and discount rate	The discount rate ranges from 4.75% to 5.00%. The average remaining years for our lease are 1.21 years as of June 30, 2022

New Drug Application (Details N

New Drug Application (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($)
R&D expense	$ 3,117,218

Related Party Transactions (Det

Related Party Transactions (Details) - Director [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement [Line Items]
Salaries	$ 60,000	$ 0	$ 360,000	$ 250,000
Short-term employee benefits	598	602	1,181	1,185
Stock-based compensation	349,259	184,827	411,526	414,015
Total	$ 409,857	$ 185,429	$ 772,707	$ 665,200

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - USD ($)		6 Months Ended
	May 11, 2022	Jun. 30, 2022	Jun. 30, 2021
Corporate Legal Counsel [Member]
Statement [Line Items]
Amounts paid contract for services		$ 242,500	$ 173,464
Chief Financial Officers [Member]
Statement [Line Items]
Amounts paid contract for services		$ 40,000	$ 240,000
James G. Robinson [Member]
Statement [Line Items]
Compensation shares	324,777
Issued shares of long and outstanding service	235,346
Purchase price		$ 1.65
Total value		$ 1,900,000
Warrants purchase		1,151,515
Purchase shares of common stock		1,151,515
Exercise price		$ 2